Enhanced cardiac FGF23 is reported in various clinical and experimental settings of cardiac remodeling or failure, e.g., CKD, ADHF, ischemic cardiomyopathy, myocarditis, dilated cardiomyopathy, inflammatory HF, TAC-induced pressure overload, experimental MI, and ischemia reperfusion in rodents. Here, FGF23 is linked to myocardial infarction.